立体定向体部放疗拓展PD-1抑制剂在难治性复发/转移性鼻咽癌中的临床获益
本研究回顾性评估8例PD-L1阳性复发/转移性鼻咽癌患者,先接受PD-1抑制剂治疗,其中7例对PD-1抑制剂单药无反应后接受SBRT并继续原PD-1抑制剂方案。首次评估确认客观缓解率为12.5%(1/8),接受SBRT的7例中6例(85.7%)出现客观缓解,中位随访56.7个月,7例患者SBRT后中位无进展生存期8.0个月、总生存期30.8个月,2年总生存率71.0%。
要点
- 8例PD-L1阳性复发/转移性鼻咽癌中,PD-1抑制剂首次评估确认客观缓解率12.5%(1/8)。
- 7例对PD-1抑制剂单药无反应后接受SBRT,其中6例(85.7%)出现客观缓解。
- 7例患者SBRT后中位无进展生存期8.0个月、总生存期30.8个月,2年总生存率71.0%。
核心结论
- PD-1抑制剂联合SBRT在PD-L1阳性复发/转移性鼻咽癌患者中显示出有前景的抗肿瘤活性。
- 作者认为,在引入SBRT时,患者可能从疾病进展后继续免疫治疗中获益。
研究设计与样本
- 回顾性评估8例经组织学确诊为PD-L1阳性的复发/转移性鼻咽癌患者,2016年9月至2017年7月在本机构及澳门诊所连续治疗。
- 5例既往标准治疗无效,2例在根治性放化疗完成后6个月内出现疾病进展,1例拒绝接受放化疗。
- 所有患者先接受PD-1抑制剂治疗,其中7例在首次评估对PD-1抑制剂单药无反应后接受SBRT并继续原PD-1抑制剂方案。
- 只要医生认为患者有临床获益即继续治疗,停止前至少给予5个周期。
主要发现
- 中位随访时间56.7个月。
- 首次评估基于RECIST-v1.1的确认客观缓解率为12.5%(1/8)。
- 接受SBRT的7例中6例(6/7,85.7%)在SBRT后出现客观缓解。
- 仅1例患者在SBRT干预开始后95天内快速进展并死亡。
- 3例未将所有病灶暴露于照射的患者可用于评估远隔效应发生率,但远隔效应未如预期发生。
临床怎么用
- 作者认为,PD-1抑制剂联合SBRT在PD-L1阳性复发/转移性鼻咽癌患者中显示出有前景的抗肿瘤活性。
- 作者认为,在引入SBRT时,患者可能从疾病进展后继续免疫治疗中获益。
局限性
- 本研究为回顾性评估。
- 仅纳入8例患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Emerging evidence shows that immune checkpoint inhibitors lead to durable responses in a variety of cancers, including nasopharyngeal carcinoma (NPC), however, combination approaches (i.e., stereotactic body radiation therapy, SBRT) are required to extend this benefit beyond a subset of patients. This study retrospectively evaluated eight recurrent/metastatic NPC patients, to investigate how radiation could potentiate PD-1 checkpoint inhibition therapy. METHODS: Between September 2016 and July 2017, eight consecutive cases with histologically confirmed PDL1-positive status, for which prior standard therapy had been ineffective (five patients), were treated at our institution and Macao Clinics and two patients had disease progression within 6 months of completion of definitive chemoradiation, or one patient refused to receive chemoradiotherapy. All received PD-1 inhibitors first, seven of them accepted SBRT with an unmodified PD-1 inhibitors regimen after first evaluation as they were unresponsive to PD-1 inhibitors alone. Treatment was discontinued as long as patients were experiencing a clinical benefit in the opinion of the physicians and at least five cycles were given before stoppage. RESULTS: Median follow-up time was 56.7 months. The confirmed objective response rate based on RECIST-v1.1 at first evaluation was 12.5% (1/8). For the seven cases who received SBRT, six of them experience an objective response (6/7, 85.7%) after SBRT. Only one patient showed rapid progress and die within 95 days after the initiation of SBRT intervention. Three patients who did not have all lesions exposed to irradiation were available to evaluate the incidence of an abscopal effect, however, it did not occur as expected. Median PFS and OS for the seven patients were 8.0 and 30.8 months after SBRT intervention, respectively. Two-year OS as indicated was 71.0%. CONCLUSIONS: PD-1 inhibitors combined with SBRT demonstrated promising antitumor activity in patients with PD-L1 positive RM-NPC. Patients may benefit from continue immunotherapy beyond disease progression when SBRT was introduced.
引用
- Lin J, Guo Q, Guo Z, et al. Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma. Radiat Oncol. 2022. PMID: 35790987. doi:10.1186/s13014-022-02073-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。